BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment
Biocryst Pharmaceuticals Inc today announced new analyses of real-world use of oral, once-daily Orladeyo (berotralstat) that showed patients who initiated Orladeyo experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment regardless of the severity of their disease, their history of prior prophylaxis or their C1-inhibitor (C1-INH) level and function.
The data are being presented in five posters at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held at the Walter E. Washington Convention Center in Washington, D.C., from 23-26 February 2024.
Professor Jonathan Bernstein MD, Professor of Medicine at the University of Cincinnati and partner of the Bernstein Allergy Group and Bernstein Clinical Research Center, said: “These additional analyses of real-world use of Orladeyo show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with Orladeyo. From patients who live with severe disease to well-controlled patients and those who have a history of being treated with other long-term prophylaxis that carry a therapeutic burden, these data demonstrate that once patients begin oral, once-daily Orladeyo, they can experience attack control over the duration of their treatment.”
Dr Ryan Arnold, Chief Medical Officer of BioCryst, said: “We are continuing to see strong disease control with Orladeyo in the real world, including in patients with HAE who report differing baseline disease severities. These findings further demonstrate that Orladeyo can help maintain disease control in patients with lower baseline attack rates and further reduce attack rates in patients with more active disease. We continue to be encouraged by the consistent, building body of real-world evidence demonstrating the significant benefit that our oral, once-daily prophylactic therapy can provide to people living with HAE.”
The five posters being presented are:
Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes; Poster #012; Friday 23 February, 3:15-4:15pm eastern time (ET)
Consistently Low Hereditary Angioedema Attack Rates with Berotralstat Regardless of Prior Prophylaxis: Real-World Outcomes; Poster #008; Friday 23 February, 3:15-4:15pm ET
Real-World Effectiveness of Berotralstat in HAE With and Without C1-Inhibitor Deficiency; Poster #281; Saturday, 24 February, 9:45-10:45am ET
Assessment of the Tolerability and Effectiveness of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: BeroLife Study Interim Analysis; Poster #028; Friday 23 February, 3:15-4:15pm ET
Evaluation of Adherence to Berotralstat in Patients with Hereditary Angioedema: A Prospective Survey in Community Pharmacies; Poster #023; Friday 23 February, 3:15-4:15pm ET
(Source: BioCryst)
